Vernalis appoints new CEO and CFO
From May 2007 until September 2008, Mr Garland was CEO of Acambis, a company engaged in the development of novel vaccines. During this period he oversaw a series
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.
This alliance combines Patheon’s experience and expertise in formulation development with Solvias’s reputation of excellence in pre-formulation and solid state chemistry. The partnering of Patheon and Solvias will